Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314185 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10GAAKDM4ELMNA | |
| SCHEMBL31315628 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10GAAKDM4ELMNA | |
| SCHEMBL18705376 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10GAAKDM4ELMNA | |
| SCHEMBL29791776 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HSD17B10GAAKDM4EMEN1 | |
| SCHEMBL17769033 | 0.78 | TYMS (0.48) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL21881721 | 0.77 | APEX1 (0.38) | ALDH1A1GAAKDM4ELMNAMEN1 | |
| SCHEMBL11109865 | 0.76 | MAOB (0.45) | ALDH1A1HSD17B10KDM4E | |
| SCHEMBL18705354 | 0.76 | MAOA (0.35) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL23771080 | 0.75 | POLB (0.39) | ALDH1A1HSD17B10GAAKDM4EMEN1 | |
| SCHEMBL31084351 | 0.75 | POLB (0.39) | ALDH1A1HSD17B10GAAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724824-B | 3- (amidoalkylthio) phthalide compound, preparation method and application thereof | 四川大学 | 2024-03-15 | — | — | CN | claimed |
| CN-115724824-A | 3- (amidoalkylthio) phthalide compound, preparation method and application thereof | 四川大学 | 2023-03-03 | — | — | CN | claimed |
| CN-108794405-B | Method for continuously preparing Olaparib intermediate by adopting micro-channel modular reaction device | 南京工业大学 | 2020-09-04 | — | — | CN | claimed |
| EP-2203783-A2 | THICK FILM RESISTS | AZ Electronic Materials USA Corp. (US) | 2010-07-07 | — | — | EP | claimed |
| US-7566707-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-28 | — | — | US | claimed |
| WO-2009040661-A2 | THICK FILM RESISTS | AZ ELECTRONIC MATERIALS USA CORP. (DE) | 2009-04-02 | — | — | WO | claimed |
| US-20090081589-A1 | THICK FILM RESISTS | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | claimed |
| US-20090022686-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-22 | — | — | US | claimed |
| EP-1517687-B1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-06-20 | — | — | EP | claimed |
| EP-1562903-A4 | MUCIN SYNTHESIS INHIBITORS | GENAERA CORP (US) | 2006-09-20 | — | — | EP | claimed |
| WO-2004000310-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | claimed |
| US-20030236220-A1 | MUCIN SYNTHESIS INHIBITORS | GENAERA CORPORATION (US) | 2003-12-25 | — | — | US | claimed |
| US-6593355-B2 | 2-phenylaminomethyl benzimidazole derivatives | BOEHRINGER INGELEHIM PHARMA KG (DE) | 2003-07-15 | — | — | US | claimed |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | claimed |
| EP-1095025-B1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-12-11 | — | — | EP | claimed |
| EP-0443533-B1 | Positive photoresist composition | FUJI PHOTO FILM CO LTD (JP) | 1998-09-30 | — | — | EP | claimed |
| EP-0443533-A2 | Positive photoresist composition | FUJI PHOTO FILM CO., LTD. (JP) | 1991-08-28 | — | — | EP | claimed |
| EP-0427031-A2 | N-aryl-nitrogen heterocycles | BAYER AG (DE) | 1991-05-15 | — | — | EP | claimed |
| EP-0061765-A1 | Beta-Lactams | E.R. SQUIBB & SONS, INC. (US) | 1982-10-06 | — | — | EP | claimed |
| US-4213969-A | Phosphonous acid derivatives, processes for their preparation and their use in combatting microorganisms | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022686-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | IL5, TSLP, TLR5 | ALDH1A1 1668/4885HSD17B10 1662/4885GAA 1783/4885 |
| US-20030236220-A1 | MUCIN SYNTHESIS INHIBITORS | MUC1, CFTR, SERPINB1 | ALDH1A1 1261/4885HSD17B10 2176/4885GAA 210/4885 |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | ALDH1A1 232/4885HSD17B10 4035/4885GAA 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.